Liver Transplant News and Research

RSS

When a patient presents with end stage liver disease or liver failure he or she may be considered for a liver transplantation. The first step in this is often a rigorous assessment and being placed on a waiting list.

The California Chronic Care Coalition launches new website to share information on chronic conditions

The California Chronic Care Coalition (CCCC) continues to advance its work toward meaningful and responsible health care reform with the launching of its consumer website: www.chroniccareca.org. Designed to help build a healthier California, the website is aimed at the more than 16 million Californians with chronic conditions such as Asthma, Diabetes, Alzheimer’s Heart disease, Epilepsy and Multiple Sclerosis.

24 Aug 2009

Study unveils detrimental effects of high-dose ursodeoxycholic acid on patients with PSC

Primary sclerosing cholangitis (PSC) is an uncommon chronic liver disease characterized by progressive inflammation and destruction of the bile ducts. The disease progresses slowly, usually leading to biliary cirrhosis, portal hypertension and liver failure over a 10-15 year period. PSC is a common cause of adult cholestatic liver diseases and a primary source behind many of the liver transplantations in U.S. adults. At least 70% of PSC cases are associated with chronic inflammatory bowel disease (IBD), usually ulcerative colitis. Currently, there is no cure for PSC and prospective treatments remain ineffective.

20 Aug 2009

Novel treatment reduces swollen livers

Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.

16 Aug 2009

Potter: Insurers use 'scare tactics' to oppose reform, disrupt town halls

Wendell Potter, a former Cigna vice president turned industry critic, is charging that insurers are inciting opposition to health reform and that there is an indirect link between insurers and disruptive town hall protests, Roll Call reports.

13 Aug 2009

Inhibitex reports Q2 2009 financials

Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the second quarter ended June 30, 2009. The Company held cash, cash equivalents and short-term investments of $24.5 million at June 30, 2009, as compared to $33.1 million at December 31, 2008.

12 Aug 2009

Metabolic bone disease in cirrhosis patients

Long-standing liver disease has long been recognized to result in fragile bones with increased risk of fractures. In various international studies, the overall incidence has varied from 11% to 48%, with a fracture rate of 3%-44%.

10 Aug 2009

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Jefferson names endowed Professorship in transplant surgery

Cataldo Doria, M.D., Ph.D., F.A.C.S., director, Division of Transplant Surgery, in the Department of Surgery at Thomas Jefferson University Hospital, has been named the Nicoletti Family Professor of Transplant Surgery. This endowed professorship is a generous gift of Robert and Beatrice Nicoletti and their family. The family cited the care they received at Jefferson when Robert received a new kidney donated by his own daughter, as the reason for their donation.

4 Aug 2009

The extremes of BMI a cause for concern in liver transplantation

A recent study by doctors at the University of Washington explained that patients who are significantly underweight or very severely obese prior to liver transplantation are at increased risk of death following transplantation surgery.

4 Aug 2009

Mortality rates higher in hepatitis C virus carriers

Hepatitis C virus (HCV) is a blood-borne disease that causes inflammation of the liver and to which there is currently no vaccine available. The World Health Organization (WHO) estimates that 3% of the world's population, approximately 170 million people, are infected with HCV and it is a leading cause of liver cirrhosis, end stage liver disease, hepatocellular carcinoma (HCC) and liver transplantation.

31 Jul 2009

Young binge drinker dies after he was refused a liver transplant

A 22 year old British man who was refused a liver transplant has died from cirrhosis of the liver after a binge-drinking habit which began when he was age 13.

22 Jul 2009

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.

22 Jul 2009

Sometimes insurance no match for health costs

Americans with serious illnesses who must often choose between paying a mortgage or their health premiums and deductibles are often going broke, The Seattle Times reports.

30 Jun 2009

New pathology tests double sensitivity to detect bile duct and pancreatic cancers

Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease. Researchers have developed new tests that double the ability to detect bile duct and pancreatic cancers, according to a Mayo Clinic study published in the June issue of Gastroenterology.

1 Jun 2009

Discovery of genetic cause for primary biliary cirrhosis

Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause.

27 May 2009

Scientists create human monoclonal antibody that neutralizes the Hepatitis C virus

Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV).

5 May 2009

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

29 Apr 2009

Transplant physicians express serious concern about organ procurement practices in China

The globalization of health care and the growth of "transplant tourism" (traveling abroad to purchase donor organs and undergo organ transplantation) have outpaced the implementation of internationally accepted ethical standards for procurement of organs for transplantation.

22 Apr 2009

Early treatment for hepatitis C offers a good chance of a cure

Australian researchers say as many as 70% of hepatitis C carriers can possibly be cured of the disease with early treatment - this is excellent news as hepatitis C, if left untreated can lead to serious liver disease.

22 Apr 2009

Grapefruit juice boosts efficacy of drug rapamycin

In a small, early clinical trial, researchers at the University of Chicago Medical Center have found that combining eight ounces of grapefruit juice with the drug rapamycin can increase drug levels, allowing lower doses of the drug to be given.

20 Apr 2009